Specialty Pharmacy

Myriad reasons may prevent patients from accessing specialty drugs, which create significant problems for patients in need of treatment.

Antiretroviral drug treatment was not found to be a cause of the higher prevalence of hypertension in persons infected with HIV.

Tim Boonstra, RPh, Pharmacy Manager at Fairview Center for Bleeding and Clotting Disorders, discusses how pharmacokinetics has helped patients with hemophilia better manage their disease.

The single-dose, prefilled autoinjector for tocilizumab (Actemra) offers an additional option for patients with rheumatoid arthritis, giant cell arteritis, and 2 forms of juvenile arthritis.

Tailoring hepatitis C treatments to shorten regimen length can reduce costs and ease burden for patients with limited insurance benefits.

Cellular proliferation predominantly drives HIV persistence on antiretroviral therapy, according to a new study.

With this approval, venetoclax (Venclexta) offers a new treatment option for individuals who are unable to tolerate standard intensive chemotherapy.

Glasdegib (Daurismo) is the first and only Hedgehog pathway inhibitor approved for the treatment of acute myeloid leukemia.

Mike Agostino, RPh, President of the National Association of Specialty Pharmacy (NASP), discusses the specialty pharmacist's role in taking a value-based approach to patient care.

Top news of the day from across the health care landscape.

Tivozanib (Fotivda) improved progression-free survival and reduced risk of death in patients with highly refractory advanced or metastatic disease.

Hispanic adults in the US who are infected with human immunodeficiency virus face a greater risk of cancers caused by human papillomavirus (HPV) than Hispanics in the general public.

Stopping treatment with fingolimod (Gilenya) can cause the disease to become much worse than before the medicine was started or while it was being taken, FDA officials warned.

Emapalumab (Gamifant) is the first treatment specifically approved for primary hemophagocytic lymphohistiocytosis, a rare and life-threatening immune disease.

Study identifies potential biomarkers that could provide a quicker path to diagnosis of amyotrophic lateral sclerosis.

Top news of the day from across the health care landscape.

New study finds that ocrelizumab (Ocrevus) has the capability to reduce risk of upper extremity disability progression in patients with primary progressive multiple sclerosis (PPMS).

Lasmiditan’s mechanism is distinct from other therapies and, if approved, represents significant innovation in the acute treatment of migraine.

A new study shows high prevalence of atopic dermatitis among adults, illustrating the need for more available treatment options.

Nick Calla, RPh, vice president of Industry Relations at Cardinal Health Specialty Solutions, discusses how specialty pharmacies can use technology to enhance patient care.

Top news of the day from across the health care landscape.

The FDA expanded the label for eltrombopag (Promacta) to now include indication for adults and pediatric patients 2 years and older with severe aplastic anemia in combination with standard immunosuppressive therapy.

The FDA has expanded the approved use of Seattle Genetics’ Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

A look at last week's top stories in the world of pharmacy.

The statement is intended to serve as a discussion guide for the risk factors, diagnosis, treatment and prevention of the disease.

NYU Langone Health discusses the challenges and benefits involved in starting or expanding a health system’s specialty pharmacy.

Study evaluates the association between body mass index in late adolescence and the incidence of pancreatic cancer in adulthood.

The FDA granted the designation to brentuximab vedotin (Adcetris) for this indication in combination with cyclophosphamide, doxorubicin, and prednisone.